The pharmaceutical landscape is undergoing a profound transformation with the rise of Live Biotherapeutic Products (LBPs). Unlike traditional small-molecule drugs or biologics, LBPs are living organisms—typically engineered or naturally occurring bacteria—designed to prevent, treat, or cure diseases by interacting directly with the human microbiome. While the therapeutic potential...